Selenium Sulfide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Selenium Sulfide
- Selenium Sulfide: From Seborrheic Dermatitis to Vulvar Inverted Follicular Keratosis
Selenium Sulfide: From Seborrheic Dermatitis to Vulvar Inverted Follicular Keratosis
One-Sentence Summary
Selenium sulfide is a topical agent originally used for seborrheic dermatitis, pityriasis versicolor and related scaling skin conditions. The TxGNN model predicts it may be effective for vulvar inverted follicular keratosis, but no clinical trials and no publications currently support this prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Seborrheic dermatitis, pityriasis simplex, seborrheic keratosis, pityriasis versicolor |
| Predicted New Indication | Vulvar inverted follicular keratosis |
| TxGNN Prediction Score | 89.52% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, selenium sulfide is a topical agent with sebostatic, keratolytic and antifungal (anti-Malassezia) properties. Its efficacy in seborrheic dermatitis and pityriasis versicolor is established, and mechanistically it may be applicable to benign keratinocytic lesions.
Inverted follicular keratosis is a benign keratinocytic lesion related to seborrheic keratosis, which is one of the drug's listed original indications. This similarity is the most likely reason the model ranks it highly. The link is a model prediction only and has not been verified.
Two further concerns apply. No trials or publications address the vulvar site. Selenium sulfide is also a known skin irritant, so tolerability on vulvar mucosa is a concern.
Other predicted indications in the same list were also reviewed:
- Cutaneous candidiasis (score 83.86%, Evidence Level L4): This is the only other prediction with any literature (two older narrative reviews, 1986 and 1995, on superficial Pityrosporum and Candida infections). Extending antifungal activity from Malassezia to Candida is plausible, but the support is indirect. Effective azole and polyene antifungals already exist, so the added value is low.
- Acne (score 65.49%) and acne keloidalis nuchae (score 79.87%): These are plausible dermatologic targets through sebostatic, keratolytic or antimicrobial effects, but nothing has been tested.
- Remaining predictions (acrodermatitis chronica atrophicans, dermatomyositis variants, childhood interstitial lung disease, familial hydroa vacciniforme, familial lichen planus): No plausible mechanism or clinical evidence was found. These are most likely artefacts of knowledge-graph associations.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature is available for the top-ranked indication. The only related literature in this prediction set concerns cutaneous candidiasis (rank 2):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3459338 | 1986 | Review | Acta Derm Venereol Suppl | Treatment of Pityrosporum and Candida skin infections. Predisposing factors drive recurrence and chronicity. |
| 7501581 | 1995 | Review | Postgrad Med | Diagnosis and topical treatment of superficial fungal infections, including cutaneous candidiasis and tinea versicolor. |
Neither review's available text shows direct Candida efficacy data for selenium sulfide.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN10324P | SELDRON CLEANING LOTION 2.5% w/v (ICM Pharma Pte. Ltd.) | Lotion | Not stated in the registration record |
Safety Considerations
- Contraindications (knowledge graph, not label text): The knowledge graph lists dermatitis as a contraindicated disease for this drug. This should be checked against the package insert.
- Drug Interactions: 79 potential interactions were identified. The 20 shown in the data compiled for this report include pantoprazole, metformin, omeprazole, triamcinolone, prednisone, warfarin, simvastatin and dexamethasone. None has a severity grade, so their clinical significance is unknown. Systemic absorption from topical use is generally low, so the practical relevance is probably limited.
- Site-specific concerns: Selenium sulfide is an irritant. Use on vulvar mucosa, or in neonates where percutaneous absorption of selenium is a concern, would need careful assessment.
Please refer to the package insert for the remaining safety information, such as warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone (Evidence Level L5). There are no trials or publications for vulvar inverted follicular keratosis, and mucosal irritation is a real concern. The nearest supported direction is cutaneous candidiasis, but its evidence is indirect and existing therapies are adequate.
To proceed, the following is needed:
- The package insert warnings and contraindications from the HSA, which is currently a blocking gap for safety screening
- Detailed mechanism of action data (for example from DrugBank)
- Clinical or case-based evidence in inverted follicular keratosis, or evidence of direct anti-Candida efficacy
- A tolerability assessment for vulvar and mucosal application
- The approved indication text for the Singapore product
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.